![Eric Xiao](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eric Xiao
Directeur/Membre du Conseil chez Emboline, Inc.
Profil
Eric Xiao is currently a Director at Emboline, Inc. He previously worked as a Principal at Matrix Capital Management Co. LP from 2018 to 2022 and as a Board Member at Palleon Pharmaceuticals, Inc. from 2020 to 2022.
Mr. Xiao completed his undergraduate degree at Yale University in 2016.
Postes actifs de Eric Xiao
Sociétés | Poste | Début |
---|---|---|
Emboline, Inc.
![]() Emboline, Inc. Medical SpecialtiesHealth Technology Emboline, Inc develops cardiovascular embolic protection devices for transcatheter and surgical cardiac procedures. Its portfolio of products include the Emboline Complete Accessible Protection, a technology that offers embolic protection of the arterial bed; and the Emboliner, a conventional embolic deflector to protect just the cerebral arteries. It serves cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventiional electrophysiology markets. The company was founded by Amir Belson and is headquartered in Santa Cruz, CA. | Directeur/Membre du Conseil | 25/05/2021 |
Anciens postes connus de Eric Xiao
Sociétés | Poste | Fin |
---|---|---|
Matrix Capital Management Co. LP
![]() Matrix Capital Management Co. LP Investment ManagersFinance Matrix Capital Management Co. LP (Matrix) is an independent, SEC-registered investment adviser and hedge fund manager headquartered in Waltham, Massachusetts. The firm was founded by David E. Goel and Paul J. Ferri in 1999. Matrix serves as the manager or management firm with discretionary investment authority to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Corporate Officer/Principal | 01/02/2022 |
Palleon Pharmaceuticals, Inc.
![]() Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/02/2022 |
Formation de Eric Xiao
Yale University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Emboline, Inc.
![]() Emboline, Inc. Medical SpecialtiesHealth Technology Emboline, Inc develops cardiovascular embolic protection devices for transcatheter and surgical cardiac procedures. Its portfolio of products include the Emboline Complete Accessible Protection, a technology that offers embolic protection of the arterial bed; and the Emboliner, a conventional embolic deflector to protect just the cerebral arteries. It serves cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventiional electrophysiology markets. The company was founded by Amir Belson and is headquartered in Santa Cruz, CA. | Health Technology |
Matrix Capital Management Co. LP
![]() Matrix Capital Management Co. LP Investment ManagersFinance Matrix Capital Management Co. LP (Matrix) is an independent, SEC-registered investment adviser and hedge fund manager headquartered in Waltham, Massachusetts. The firm was founded by David E. Goel and Paul J. Ferri in 1999. Matrix serves as the manager or management firm with discretionary investment authority to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Finance |
Palleon Pharmaceuticals, Inc.
![]() Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |